ESR1 and breast cancer: The results of this study suggest that PIs efficiently inhibit ERα/HER2 cross-talk pathways through blocking ERα expression, as well as through inhibiting HER2 activation via stabilization of BDP1, which leads to the death of ER+/HER2+ breast cancer cells.